drugset / Trial / NCT07453784

Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation

NCT07453784

Phase 1 Recruiting 44 enrolled Abivax S.A. Quotient Sciences · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The sponsor is developing a pediatric minitablet formulation as part of the overall pharmaceutical development strategy. In vitro dissolution and physiological-based bio-pharmaceutics modelling and simulation have been used to guide the development of the mini-tablet formulation to match the PK exposure of the adult capsule formulation. The study aims to investigate the relative bioavailability of the 50mg minitablet compared to the adult obefazimod 50 mg capsule in adult healthy volunteers.

Timeline

Start
2026-03-03
Primary completion
2026-09
Completion
2026-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Obefazimod Small molecule 50 mg Oral

Indications

No indication recorded.